BSA modified, disulfide-bridged mesoporous silica with low biotoxicity for dual-responsive drug delivery
| Autor: | Yuhuan Zhang, Qiwen Chen, Shiguo Sun, Junna Lu, Fengyu Liu, Su-Shing Chen, Yongqian Xu, Jia Wen, Xingcheng Ding, Hongjuan Li |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug
Biocompatibility biology Chemistry media_common.quotation_subject Serum albumin Nanoparticle 02 engineering and technology General Chemistry Glutathione Mesoporous silica 010402 general chemistry 021001 nanoscience & nanotechnology Condensed Matter Physics 01 natural sciences Combinatorial chemistry 0104 chemical sciences chemistry.chemical_compound Mechanics of Materials Drug delivery biology.protein General Materials Science Nanocarriers 0210 nano-technology media_common |
| Zdroj: | Microporous and Mesoporous Materials. 278:257-266 |
| ISSN: | 1387-1811 |
| DOI: | 10.1016/j.micromeso.2018.12.001 |
| Popis: | Siliceous materials based intelligent drug delivery systems (DDS) have attracted numerous attentions. Unfortunately, their intrinsic biologic inertia and non-degradability are critical issues need to be addressed because it hampers further clinical translation application. Herein, disulfide-bridged mesoporous silica nanoparticles (designed as mSiO2(s-s)) have been synthesized through nucleophilic substitution reaction, which have biodegradability in simulative tumor reducing conditions. Furthermore, folic acid (FA) decorated bull serum albumin (BSA) has been modified onto the surface of mSiO2(s-s) to improve tissue biocompatibility, prevent anticancer drugs leakage and endow effective targeting capacity. Therefore, the nanoparticles present good biodegradability, tissue biocompatibility, tumor cell targeting capacity and pH/glutathione (GSH) dual-responsive drug release capacity. This novel drug nanocarrier possesses biosafety and effective anti-cancer strategy, provides significant promising in future biomedical application. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect